Psoriasis after exposure to angiotensin converting enzyme inhibitors: clinical features of a signal from the WHO pharmacovigilance database

Brahim Azzouz; Manuelle Viguier; Thierry Trenque

doi:10.1016/j.jaad.2024.10.102

Psoriasis after exposure to angiotensin converting enzyme inhibitors: clinical features of a signal from the WHO pharmacovigilance database

J Am Acad Dermatol. 2024 Nov 23:S0190-9622(24)03252-3. doi: 10.1016/j.jaad.2024.10.102. Online ahead of print.

Authors

Brahim Azzouz¹, Manuelle Viguier², Thierry Trenque³

Affiliations

¹ Université de Reims Champagne-Ardenne, VIEFRA, CHU de Reims, Centre Régional de Pharmacovigilance de Reims, Reims, France. Electronic address: bazzouz@chu-reims.fr.
² Université de Reims Champagne-Ardenne, IRMAIC, CHU de Reims, Service de Dermatologie, Reims, France.
³ Université de Reims Champagne-Ardenne, VIEFRA, CHU de Reims, Centre Régional de Pharmacovigilance de Reims, Reims, France.

PMID: 39586329
DOI: 10.1016/j.jaad.2024.10.102

No abstract available

Keywords: angiotensin converting enzyme inhibitors; erythrodermic psoriasis; pharmacovigilance; plaque psoriasis; pustular psoriasis; quality of life.